199807-35-7 Usage
Uses
Used in Pharmaceutical Industry:
Cilengitide trifluoroacetate is used as an anti-angiogenic agent for its potential role in treating conditions that involve excessive angiogenesis, such as cancer. By inhibiting the integrins αvβ3 and αvβ5, it can impede the growth of new blood vessels, which is a critical factor in tumor progression.
Used in Cancer Research:
Cilengitide trifluoroacetate is used as a research compound for studying the mechanisms of angiogenesis and the role of integrins in cancer development. Despite not meeting the expectations in phase III clinical trials for glioblastoma, its potential in other cancer types and its mechanism of action continue to be of interest in the scientific community.
Used in Drug Development:
Cilengitide trifluoroacetate is used as a lead compound in the development of new drugs targeting angiogenesis. The understanding of its interaction with integrins αvβ3 and αvβ5 can guide the design of novel therapeutics that may be more effective or have fewer side effects in the treatment of cancer and other angiogenesis-related diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 199807-35-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,9,8,0 and 7 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 199807-35:
(8*1)+(7*9)+(6*9)+(5*8)+(4*0)+(3*7)+(2*3)+(1*5)=197
197 % 10 = 7
So 199807-35-7 is a valid CAS Registry Number.
199807-35-7Relevant academic research and scientific papers
Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
-
Page/Page column 19-20, (2008/06/13)
The invention teaches methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amount of an antagonist sufficient to inhibit angiogenesis in combination with a therapeutic amoun
